170 related articles for article (PubMed ID: 11271220)
1. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
4. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
5. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.
Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM
Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
7. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
Sperschneider H; Wagner C; Korn A; Christians U
Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
[TBL] [Abstract][Full Text] [Related]
8. Neoral induction in pediatric renal transplantation.
Bunchman TE; Parekh RS; Flynn JT; Smoyer WE; Kershaw DB; Valentini RP; Pontillo BJ; Sandvordenker J; Brown C; Sedman AB
Pediatr Nephrol; 1998 Jan; 12(1):2-5. PubMed ID: 9502556
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
10. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
[TBL] [Abstract][Full Text] [Related]
11. Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients.
Taesch S; Niese D; Mueller EA
Transplant Proc; 1994 Dec; 26(6):3147-9. PubMed ID: 7998097
[No Abstract] [Full Text] [Related]
12. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
14. Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients.
Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
Transpl Int; 1994; 7 Suppl 1():S267-9. PubMed ID: 11271221
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral.
Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J
Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114
[TBL] [Abstract][Full Text] [Related]
16. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients.
Bistrup C; Nielsen FT; Jeppesen UE; Dieperink H
Nephrol Dial Transplant; 2001 Feb; 16(2):373-7. PubMed ID: 11158415
[TBL] [Abstract][Full Text] [Related]
17. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
18. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant.
De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA
Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239
[No Abstract] [Full Text] [Related]
19. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
Noble S; Markham A
Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
[TBL] [Abstract][Full Text] [Related]
20. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
